Add BrightSurf on Google Email

UCLA researchers awarded $1.7 million Department of Defense grant to advance next-generation CAR T-cell therapies for prostate cancer

Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.

Why some cancers are worse than others

Researchers found that smaller tetraploid cancer cells are more aggressive and tumorigenic, associated with worse prognosis and lower survival rates in several cancer types. This discovery challenges the conventional understanding of tetraploidy's role in cancer progression.

SourceVirginia Tech·JournalProceedings of the National Academy of Sciences·DateMay 25, 2026

Why cell therapy cancer treatment sometimes fails

Researchers found that patients with high senescence burdens in their CD8+ T cells were more likely to fail treatment, while those with youthful profiles responded better. The study identified three transcription factors controlling the senescence program, which can be targeted to improve treatment outcomes.

SourceRutgers University·JournalCell Reports·DateApr 29, 2026

Targeting the yin and yang of macrophages to strengthen cancer vaccines and anti-tumor immunity

A study by Geisel School of Medicine researchers identifies specific macrophage populations that help coordinate anti-tumor immunity, while others support tumor growth. By selectively targeting these immune programs, cancer treatments may be improved without eliminating entire immune cell populations.

SourceThe Geisel School of Medicine at Dartmouth·JournalNature Immunology·TypeExperimental study·DateApr 21, 2026

Cellular neighborhoods inside tumors may predict which patients with melanoma benefit from combination immunotherapy

Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.

AACR: Targeted drug delivery for colorectal cancer, COVID-19’s impact on breast cancer outcomes, AI in cancer diagnosis and more

UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.

The University of Colorado Anschutz Gates Institute achieves first-in-U.S. FDA clearance for campus-built CAR T-cell therapy

The University of Colorado Anschutz Gates Institute has achieved first-in-U.S. FDA clearance for a novel CAR T-cell therapy targeting aggressive leukemia cells, representing a potential new treatment approach for patients with hard-to-treat disease. The therapy will be evaluated in a Phase 1 clinical trial starting this summer.

Chemotherapy candidate can marshall attention from the body’s natural defenses

Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.

SourceUniversity of Texas at Austin·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 11, 2026

Wistar scientists develop two-vaccine strategy to fight t cell lymphoma

Scientists at The Wistar Institute have designed a two-vaccine approach targeting T cell receptors and cancer-specific mutations, significantly improving tumor control and survival in preclinical models. The combination therapy, developed in collaboration with Geneos Therapeutics, offers a promising new tool for treating T cell lymphom...

SourceThe Wistar Institute·JournalCancer Immunology Immunotherapy·TypeExperimental study·DateMar 10, 2026

Overcoming ovarian cancer’s resistance to immunotherapy

A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...

SourceSanford Burnham Prebys·JournalCell Reports·TypeExperimental study·DateMar 5, 2026

Scientists report landmark “evolutionary double-bind” strategy to overcome treatment resistance in prostate cancer

Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...

New biomarker predicts chemotherapy response in triple-negative breast cancer

Researchers developed a new computational approach to predict chemotherapy response in triple-negative breast cancer, outperforming current methods. The TmS biomarker accurately sorts patients into those with favorable or poor prognosis, highlighting its potential as an effective starting point for patient stratification.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalCell Reports Medicine·DateFeb 17, 2026

The Frontiers of Knowledge Award goes to Carl June and Michel Sadelain for revolutionizing cancer treatment using immunotherapy based on the patient’s own genetically modified cells

Researchers have developed a breakthrough technique to transform a patient's own T cells into soldiers trained to recognize and kill cancer cells, benefiting tens of thousands of individuals with blood cancers. The approach is now being explored for solid tumors and other diseases.

Multiple myeloma: Established cancer drug reactivates immunotherapy

Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.

SourceTechnical University of Munich (TUM)·JournalBlood·TypeExperimental study·DateFeb 11, 2026

Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus

Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalClinical Cancer Research·DateFeb 10, 2026

Could these two genes make T cells unstoppable?

Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.

SourceSalk Institute·JournalNature·DateFeb 4, 2026

Chinese Medical Journal article review: cGAS‑STING pathway emerges as cornerstone for next‑generation immunotherapies

The cGAS-STING pathway plays a crucial role in detecting cellular DNA, triggering type I interferons and cytokines, and modulating immune responses. Its therapeutic potential is being explored in cancer and various diseases, with promising preclinical evidence suggesting its potential as a target for next-generation immunotherapies.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·DateJan 26, 2026